Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Size, Growth and Insights by Treatment (Drug Class (Mitogen-Activated Protein Kinases (MAPK) Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors, Others), Oxygen Therapy, Lung Transplant, Others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2032

Table of Contents

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Overview

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

Chapter 6. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment

6.1 Overview

6.2 Drug Class

6.2.1 MAPK Inhibitors

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.2.2 Tyrosine Kinase Inhibitors

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.2.3 Autotaxin Inhibitors

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.2.4 Others

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.3 Oxygen Therapy

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.4 Lung Transplant

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

6.5 Others

Market Estimates & Forecast, by Region, 2022-2030

Market Estimates & Forecast, by Country, 2022-2030

Chapter 7. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Region

7.1 Overview

7.2 Americas

7.2.1 North America

7.2.1.1 US

7.2.1.2 Canada

7.2.2 Latin America

7.3 Europe

7.3.1 Western Europe

7.3.1.1 Germany

7.3.1.2 France

7.3.1.3 Italy

7.3.1.4 Spain

7.3.1.5 UK

7.3.1.6 Rest of Western Europe

7.3.2 Eastern Europe

7.4 Asia-Pacific

7.4.1 Japan

7.4.2 China

7.4.3 India

7.4.4 Australia

7.4.5 South Korea

7.4.6 Rest of Asia-Pacific

7.5 Middle East & Africa

7.5.1 Middle East

7.5.2 Africa

Chapter 8. Company Landscape

8.1 Overview

8.2 Competitive Analysis

Chapter 9. Company Profile

9.1 Biogen

9.1.1 Company Overview

9.1.2 Product Type Overview

9.1.3 Financials Overview

9.1.4 Key Developments

9.1.5 SWOT Analysis

9.2 Boehringer Ingelheim GMBH

9.2.1 Company Overview

9.2.2 Product Type Overview

9.2.3 Financial Overview

9.2.4 Key Developments

9.2.5 SWOT Analysis

9.3 Bristol-Myers Squibb Company

9.3.1 Company Overview

9.3.2 Product Type Overview

9.3.3 Financial Overview

9.3.4 Key Development

9.3.5 SWOT Analysis

9.4 Cipla

9.4.1 Company Overview

9.4.2 Product Type Overview

9.4.3 Financial Overview

9.4.4 Key Development

9.4.5 SWOT Analysis

9.5 F. Hoffmann-La Roche AG

9.5.1 Company Overview

9.5.2 Product Type Overview

9.5.3 Financial overview

9.5.4 Key Developments

9.5.5 SWOT Analysis

9.6 Fibrogen, Inc.

9.6.1 Company Overview

9.6.2 Product Type Overview

9.6.3 Financial Overview

9.6.4 Key Developments

9.6.5 SWOT Analysis

9.7 Galapagos NV

9.7.1 Overview

9.7.2 Product Type Overview

9.7.3 Financial Overview

9.7.4 Key Developments

9.7.5 SWOT Analysis

9.8 Medicinova, Inc.

9.8.1 Overview

9.8.2 Product Type Overview

9.8.3 Financials

9.8.4 Key Developments

9.8.5 SWOT Analysis

9.9 Merck & Co., Inc.

9.9.1 Overview

9.9.2 Product Type Overview

9.9.3 Financials

9.9.4 Key Developments

9.9.5 SWOT Analysis

9.10 Novartis AG

9.10.1 Overview

9.10.2 Product Type Overview

9.10.3 Financials

9.10.4 Key Developments

9.10.5 SWOT Analysis

9.11 Prometic Life Sciences Inc.

9.11.1 Overview

9.11.2 Product Type Overview

9.11.3 Financials

9.11.4 Key Developments

9.11.5 SWOT Analysis

9.12 Others

Chapter 10 Appendix

10.1 References

10.2 Related Reports

LIST OF TABLES

Table 1 Global Idiopathic Pulmonary Fibrosis Treatment Market Synopsis, 2022–2030

Table 2 Global Idiopathic Pulmonary Fibrosis Treatment Market Estimates and Forecast, 2022-2030(USD Million)

Table 3 Global Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2022-2030(USD Million)

Table 4 Global Idiopathic Pulmonary Fibrosis Treatment Market, by Region, 2022-2030(USD Million)

Table 5 North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2022-2030(USD Million)

Table 6 US: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2022-2030(USD Million)

Table 7 Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2022-2030(USD Million)

Table 8 Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2022-2030(USD Million)

Table 9 Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2022-2030(USD Million)

Table 10 Western Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2022-2030(USD Million)

Table 11 Eastern Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2022-2030(USD Million)

Table 12 Asia-Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2022-2030(USD Million)

Table 13 Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Treatment, 2022-2030(USD Million)  

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Market Structure for Global Idiopathic Pulmonary Fibrosis Treatment Market

Figure 3 Market Dynamics for Global Idiopathic Pulmonary Fibrosis Treatment Market

Figure 4 Global Idiopathic Pulmonary Fibrosis Treatment Market Share, by Treatment, 2022 (%)

Figure 5 Global Idiopathic Pulmonary Fibrosis Treatment Market Share, by Region, 2022 (%)

Figure 6 North America: Idiopathic Pulmonary Fibrosis Treatment Market Share, by Country, 2022 (%)

Figure 7 Europe: Idiopathic Pulmonary Fibrosis Treatment Market Share, by Region, 2022 (%)

Figure 8 Western Europe: Idiopathic Pulmonary Fibrosis Treatment Market Share, by Country, 2022 (%)

Figure 9 Asia-Pacific: Idiopathic Pulmonary Fibrosis Treatment Market Share, by Country, 2022 (%)

Figure 10 Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market Share, by Country, 2022 (%)

Figure 11 Global Idiopathic Pulmonary Fibrosis Treatment Market: Company Share Analysis, 2022 (%)

Figure 12 Biogen: Key Financials

Figure 13 Biogen: Segmental Revenue

Figure 14 Biogen: Geographical Revenue

Figure 15 Boehringer Ingelheim GMBH: Key Financials

Figure 16 Boehringer Ingelheim GMBH: Segmental Revenue

Figure 17 Boehringer Ingelheim GMBH: Geographical Revenue

Figure 18 Bristol-Myers Squibb Company: Key Financials

Figure 19 Bristol-Myers Squibb Company: Segmental Revenue

Figure 20 Bristol-Myers Squibb Company: Geographical Revenue

Figure 21 Cipla: Key Financials

Figure 22 Cipla: Segmental Revenue

Figure 23 Cipla: Geographical Revenue

Figure 24 F. Hoffmann-La Roche AG: Key Financials

Figure 25 F. Hoffmann-La Roche AG: Segmental Revenue

Figure 26 F. Hoffmann-La Roche AG: Geographical Revenue

Figure 27 Fibrogen, Inc.: Key Financials

Figure 28 Fibrogen, Inc.: Segmental Revenue

Figure 29 Fibrogen, Inc.: Geographical Revenue

Figure 30 Galapagos NV: Key Financials

Figure 31 Galapagos NV: Segmental Revenue

Figure 32 Galapagos NV: Geographical Revenue

Figure 33 Medicinova, Inc.: Key Financials

Figure 34 Medicinova, Inc.: Segmental Revenue

Figure 35 Medicinova, Inc.: Geographical Revenue

Figure 36 Merck & Co., Inc.: Key Financials

Figure 37 Merck & Co., Inc.: Segmental Revenue

Figure 38 Merck & Co., Inc.: Geographical Revenue

Figure 39 Novartis AG: Key Financials

Figure 40 Novartis AG: Segmental Revenue

Figure 41 Novartis AG: Geographical Revenue

Figure 42 Prometic Life Sciences Inc.: Key Financials

Figure 43 Prometic Life Sciences Inc.: Segmental Revenue

Figure 44 Prometic Life Sciences Inc.: Geographical Revenue